Molecular docking enabled updated screening of the matrix protein VP40 from Ebola virus with millions of compounds in the MCULE database for potential inhibitors.

We report a candidate lead (compound #5: ((10R)-10-(4-hydroxyphenyl)-11,12,14,16-tetraazatetracyclo[7.7.0.02,7.011,15] hexadeca-1(16), 2(7),3,5,8,12,14-heptaen-8-ol)) with high drug-likeness score, promising lead-likeness behaviour and high median lethal dose. The candidate lead compound #5 engages in hydrogen bonding and hydrophobic interactions with VP40 active site residues. Thus, the lead compound #5 is recommended for further in vitro and in vivo validations for further consideration. PMID: 31787811 [PubMed]
Source: Bioinformation - Category: Bioinformatics Authors: Tags: Bioinformation Source Type: research

Related Links:

Source: National Institutes of Health (NIH). Published: 1/14/2020. This one-hour, 44-minute presentation discusses how the National Institutes of Health (NIH) has been at the forefront in the global effort to prevent the spread of Ebola virus. NIH staff were deployed in western Africa during the 2015-2016 Ebola outbreak to provide primary care to those infected, and Ebola patients were received at the NIH Clinical Center. For many years prior, NIH scientists studied the natural reservoirs of emerging viruses such as Ebola virus and have elucidated the biology of Ebola virus infection, which has informed the creation of in...
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - Category: International Medicine & Public Health Source Type: news
(INSERM (Institut national de la sant é et de la recherche m é dicale)) Public health efforts successfully stopped human-to-human transmission of Ebola virus in West Africa in 2016 after the worst Ebola outbreak in history. Pursuing and intensifying efforts to develop a safe and effective vaccination strategy against Ebola virus disease, with durable protection in all populations, including children, is vital.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news
[Deutsche Welle] The deadly virus has killed nearly three times as many people in the Democratic Republic of Congo as any Ebola outbreak. It's preventable with a vaccine.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
(Natural News) The federal government is ramping up its Ebola propaganda campaign once again with a new announcement from the Centers for Disease Control and Prevention (CDC) about a newly released Ebola rapid diagnostics test, which just so happens to coincide with the release of a new Food and Drug Administration (FDA)-approved Ebola vaccine that...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
Although Ebola is rare in the U. S., the vaccine ’s approval will help in world-wide efforts to prevent future Ebola outbreaks and deaths.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news
On Thursday, the US Food and Drug Administration approved Ervebo, the first vaccine against Ebola to get green lit by American officials. It comes as a Congo outbreak rages on and has killed 4 in Uganda.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
by Prossy Naluyima, Willy Kayondo, Chi Ritchie, Joseph Wandege, Sharon Kagabane, Lydia Tumubeere, Brenda Kusiima, Daniel Kibombo, Sharon Atukunda, Christine Nanteza, Harriet Nabirye, Francis Bunjo Mugabi, Sarah Namuyanja, Christopher Hatcher, Hypaitia Rauch, Moses Mukembo, Patrick Musinguzi, JMEDICC Consortium , Nathan Sanders, Elizabeth Turesson, Christian Cando, Richard Walwema, Derrick Mimbe, Janice Hepburn, Danielle Clark, Mohammed Lamorde, Hannah Kibuuka, Saima Zaman, Anthony P. Cardile, Karen A. Martins Following the 2013–2016 Ebola virus outbreak in West Africa, numerous groups advocated for the importance of...
Source: PLoS Neglected Tropical Diseases - Category: Tropical Medicine Authors: Source Type: research
by Kai J. Rogers, Bethany Brunton, Laura Mallinger, Dana Bohan, Kristina M. Sevcik, Jing Chen, Natalie Ruggio, Wendy Maury BackgroundEbolavirus (EBOV) outbreaks, while sporadic, cause tremendous morbidity and mortality. No therapeutics or vaccines are currently licensed; however, a vaccine has shown promise in clinical trials. A critical step towards development of effective therapeutics is a better understanding of factors that govern host susceptibility to this pathogen. As macrophages are an important cell population targeted during virus replication, we explore the effect of cytokine polarization on macrophage infectio...
Source: PLoS Neglected Tropical Diseases - Category: Tropical Medicine Authors: Source Type: research
Recent occurrences of filoviruses and the arenavirus Lassa virus (LASV) in overlapping endemic areas of Africa highlight the need for a prophylactic vaccine that would confer protection against all of these viruses that cause lethal hemorrhagic fever (HF). We developed a quadrivalent formulation of VesiculoVax that contains recombinant vesicular stomatitis virus (rVSV) vectors expressing filovirus glycoproteins and that also contains a rVSV vector expressing the glycoprotein of a lineage IV strain of LASV. Cynomolgus macaques were vaccinated twice with the quadrivalent formulation, followed by challenge 28 days after the b...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
[New Times] Rwanda and the Democratic Republic of the Congo Sunday unveiled a massive vaccination campaign against Ebola Virus Disease (EVD) for their residents who live within the vicinity of a possible Ebola outbreak.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
More News: African Health | Bioinformatics | Databases & Libraries | Ebola | Ebola Vaccine | Outbreaks | Toxicology | Vaccines